Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Last year, 78% of the company’s sales came from products that are over 10 years old, analysts at Vantage pointed out in a report released last month.
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024.
EvaluatePharma has predicted that risdiplam could become an $800m-plus drug by 2024, and other analysts have said it could make upwards of $2.5bn at its peak.
For comparison, while Tecfidera is a billion-dollar product, EvaluatePharma has forecast sales of Vumerity to reach a modest $111m in 2024.
Evaluate Pharma projects that Palforzia could be a blockbuster drug that brings in more than $1 billion in annual sales by 2024.
Evaluate Pharma forecasts Aimovig to maintain its lead up to 2024, with estimated sales of $2.05bn that year. It also predicts Emgality could hit $1.2bn by 2024, with…
And according to Evaluate Pharma, it's a blockbuster approval. Palforzia could hit an estimated $1.28 billion in sales by 2024, the firm said, as an immunotherapy that…
EvaluatePharma has said selpercatinib could become a $500 million-plus product by 2024.
Conatus’ fate “serves to underline the risks of NASH,” Vantage wrote in June after its pan-capsase inhibitor, emricasan, failed its third NASH study.
EvaluatePharma has previously predicted that sales of ALKS 381 could reach $381m in 2024 if approved, which would be a sizeable addition to its current revenues, expected…